October 7, 2021 (Montreal, QC, Canada)
Article published in September issue of MEDTECH OUTLOOK Magazine
Ocular surface disorders (OSDs) typically indicate damage to the surface layers of the eye, namely the cornea, conjunctiva, eyelids, and lacrimal glands, causing irritation, redness, and inflammation of the eye, among other symptoms. OSDs include conditions like Dry Eye Disease (DED), Blepharitis, and Meibomian Gland Dysfunction (MGD), and affect more than 30 million people in the United States today. Reports suggest that the pandemic has also significantly furthered the risk of inducing or exacerbating OSDs, as remotization has drastically increased the time people spend in front of their screens.
Fueling the growing awareness and education around the field of OSDs, Canadian medical device company I-MED Pharma, is positioned to dominate the dry eye market with their uniquely formulated line of ocular surface disease diagnostics and treatments. Specializing in dry eye diagnosis and management, the company provides a comprehensive offering that includes viscoadaptive, preservative-free artificial tears, ocular hygiene cleansers, therapeutic accessories, nutritional supplements, punctum plugs, state-of-the-art diagnostic tools, and IRPL® treatment solutions.